Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Review

A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer

Authors: Nahla E. El-Ashmawy, Rania M. Khalil

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

l-carnitine is an antioxidant and is found to be a protective agent against many diseases including cancer. This review illustrates the possible role of l-carnitine as an add-on therapy to breast cancer patients maintained on tamoxifen. The objectives of carnitine treatment are diverse: improving tamoxifen-related side effects, offering better cancer prognosis by reducing the risk of developing cancer recurrence or metastasis, and modulating the growth factors which may be, in part, a prospective illustration to overcome tamoxifen resistance. So, it could be recommended to supplement l-carnitine to breast cancer patients starting tamoxifen treatment.
Literature
1.
Ahmad S. l-carnitine in dialysis patients. Semin Dialysis. 2001;14(3):209–17.
2.
Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol. 2008;294:R352–61.PubMed
3.
Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig. 2006;26(5):297–302.PubMed
4.
Al-Majed AA. Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007;100(3):145–50.PubMed
5.
Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol. 2009;15(11):1373–80.PubMedCentralPubMed
6.
Andreasen EB, Tranholm M, Wiinberg B, Markussen B, Kristensen AT. Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Vet Scand. 2012;54(1):3–30.PubMedCentralPubMed
7.
Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci USA. 2011;108:18879–86.PubMedCentralPubMed
8.
Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev. 2012;2012:609421–34.PubMedCentralPubMed
9.
Biolo G, Toigo G, Ciocchi B, Situlin R, Iscra F, Gullo A, et al. Metabolic response to injury and sepsis: changes in protein metabolism. Nutrition. 1997;13:52S–7S.PubMed
10.
Borghi-Silva A, Baldissera V, Sampaio LM, Pires-DiLorenzo VA, Jamami M, Demonte A, et al. l-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs. Braz J Med Biol Res. 2006;39(4):465–74.PubMed
11.
Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health. 2000;31(1):71–85.PubMed
12.
Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012;3(4):345–64.PubMedCentralPubMed
13.
Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signalling and inhibition in breast cancer. Curr Cancer Drug Ther. 2009;9:419–38.
14.
Campbell CI, Petrik JJ, Moorehead RA. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Mol Cancer. 2010;9:235–50.PubMedCentralPubMed
15.
Cao Y, Qu HJ, Li P, Wang CB, Wang LX, Han ZW. Single dose administration of l-carnitine improves antioxidant activities in healthy subjects. Tohoku J Exp Med. 2011;224(3):209–13.PubMed
16.
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006;17:1120–7.PubMed
17.
Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63(4):641–6.PubMed
18.
Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008;23:16–34.PubMed
19.
Chan AL, Leung HW, Wang SF. Multivitamin supplement use and risk of breast cancer: a meta-analysis. Ann Pharmacother. 2011;45(4):476–84.PubMed
20.
Chang B, Nishikawa M, Nishiguchi S, Inoue M. l-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer. 2005;113:719–29.PubMed
21.
Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea. 2008;27:574–9.PubMed
22.
Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. l-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004;1033:168–76.PubMed
23.
Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013;19(3):197–209.PubMedCentralPubMed
24.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedCentralPubMed
25.
Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia. 2011;13:504–15.PubMedCentralPubMed
26.
De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G. Effect of the chronic treatment with l-acetylcarnitine in Down's syndrome. Clin Ter. 1994;144(2):123–7.PubMed
27.
De Grandis D, Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 2002;3(4):223–31.PubMed
28.
De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli Jr DR, et al. l-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;39(11):1216–25.PubMed
29.
Dossus L, Kaaks R. Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008;22(4):551–71.PubMed
30.
Duffy LS, Greenberg DB, Younger J, Ferraro MG. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics. 1999;40:304–8.PubMed
31.
Dutta A, Ray K, Singh VK, Vats P, Singh SN, Singh SB. l-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp Physiol. 2008;93(10):1139–46.PubMed
32.
Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36(10):867–85.PubMedCentralPubMed
33.
Erbas H, Aydogdu N, Usta U, Erten O. Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide. Cell Biol Int. 2007;31:1414–9.PubMed
34.
Federighi G, Macchi M, Bernardi R, Scuri R, Brunelli M, Durante M, et al. Differentially expressed genes in Hirudo medicinalis ganglia after acetyl-l-carnitine treatment. PLoS One. 2013;8(1):e53605–11.PubMedCentralPubMed
35.
Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-l-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005;219(3):154–66.PubMed
36.
Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012;4(2):51–60.PubMedCentralPubMed
37.
Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of acetyl-l-carnitine: studies in vitro. J Neurosci Res. 1994;37(1):92–6.PubMed
38.
Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, et al. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat. 2004;85(1):89–97.PubMed
39.
Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, et al. Acetyl-l-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism. 2000;49(6):704–8.PubMed
40.
Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat. 2012;134(2):693–700.PubMedCentralPubMed
41.
Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10:313–25.PubMedCentralPubMed
42.
Gülçin I. Antioxidant and antiradical activities of l-carnitine. Life Sci. 2006;78(8):803–11.PubMed
43.
Gunes D, Kirkim G, Kolatan E, Guneri EA, Ozogul C, Altun Z, et al. Evaluation of the effect of acetyl l-carnitine on experimental cisplatin ototoxicity and neurotoxicity. Chemotherapy. 2011;57(3):186–94.PubMed
44.
Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, et al. Feeding acetyl-l-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99(4):1870–5.PubMedCentralPubMed
45.
Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, et al. The effect of melatonin on depression, anxiety, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ. 2012;2(1):e000647–55.
46.
47.
Hoang BX, Graeme Shaw D, Pham P, Levine SA. Neuro-bioenergetic concepts in cancer prevention and treatment. Med Hypotheses. 2007;68(4):832–43.PubMed
48.
Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31(9):664–9.PubMed
49.
Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939–46.PubMed
50.
Husain S, Crosson CE. Role of PKCepsilon in PGF2alpha-stimulated MMP-2 secretion from human ciliary muscle cells. J Ocul Pharmacol Ther. 2008;24(3):268–77.PubMedCentralPubMed
51.
Jeukendrup AE, Randell R. Fat burners: nutrition supplements that increase fat metabolism. Obes Rev. 2011;12(10):841–51.PubMed
52.
Jirillo E, Altamura M, Munno I, Pellegrino NM, Sabato R, Di Fabio S, et al. Effects of acetyl-l-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol Immunotoxicol. 1991;13(1–2):135–46.PubMed
53.
Khalil RM, Darwish H, El-Ashmawy NE, El-Bahrawy HA. l-carnitine ameliorates tamoxifen-associated adverse effects in breast cancer women. Int J Cancer Res. 2013;47(2):1149–57.
54.
Khalil RM, El-Ashmawy NE, El-Bahrawy HA, Darwish H. l-carnitine supplement to tamoxifen-treated breast cancer patients: protection against cardiovascular risk. Int J Med Sci. 2013;46(2):1245–54.
55.
Khalil RM, El-Bahrawy HA, El-Ashmawy NE, Darwish H. l-carnitine decreases Her-2/neu in breast cancer patients treated with tamoxifen. IOSR-JPBS. 2013;5(2):91–8.
56.
Kumaran S, Subathra M, Balu M, Panneerselvam C. Supplementation of l-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. Exp Aging Res. 2005;31(1):55–67.PubMed
57.
Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66(4):283–92.PubMed
58.
Landree LE, Hanlon AL, Strong DW, Rumbaugh G, Miller IM, Thupari JN, et al. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. J Biol Chem. 2004;279:3817–27.PubMed
59.
Lango R, Smoleński RT, Rogowski J, Siebert J, Wujtewicz M, Słomińska EM, et al. Propionyl-l-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther. 2005;19(4):267–75.PubMed
60.
Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol. 2009;27(31):5144–52.PubMedCentralPubMed
61.
Li H, Li QD, Wang PZ, Wang MS, Cui J, Diao TY, et al. The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line. Lipids Health Dis. 2011;10:108–18.PubMedCentralPubMed
62.
Lien EA, Anker G, Ueland PM. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Biol. 1995;55(2):229–31.PubMed
63.
Macciò A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. Sci Wor J. 2011;11:2020–36.
64.
Maestri A, De Pasquale CA, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-l-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005;91:135–8.PubMed
65.
Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, et al. Effects of l-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci. 2006;51(12):2242–7.PubMed
66.
Micheletti R, Giacalone G, Bianchi G. Effect of propionyl-l-carnitine on the mechanics of right and left papillary muscles from volume-overloaded rat hearts. J Cardiovasc Pharmacol. 1996;27(1):52–7.PubMed
67.
Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J Child Neurol. 1995;10(2):S40–4.PubMed
68.
Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003;18(2):61–71.PubMed
69.
Mook D, Felger J, Graves F, Wallen K, Wilson ME. Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques. Psychoneuroendocrinology. 2005;30(3):273–83.PubMed
70.
Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137(7):1123–30.PubMed
71.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3:269–80.PubMed
72.
Naini AE, Sadeghi M, Mortazavi M, Moghadasi M, Harandi AA. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2012;23(3):484–8.PubMed
73.
Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 2007;67:1282–90.PubMed
74.
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008;68(13):1477–86.PubMedCentralPubMed
75.
Ng VL. Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med. 2009;29:253–63.PubMed
76.
Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther. 2008;83(5):702–10.PubMedCentralPubMed
77.
Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and l-carnitine. Nutrients. 2011;3(8):735–55.PubMedCentralPubMed
78.
Palva T, Ranta H, Koivisto AM, Pylkkänen L, Cuzick J, Holli K. A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo—a substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer. 2013;49(1):45–51.PubMed
79.
Porter NS, Jason LA, Boulton A, Bothne N, Coleman B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern Complement Med. 2010;16(3):235–49.PubMed
80.
Pritchard KI, Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006;66(13):1727–40.PubMed
81.
Puca FM, Genco S, Specchio LM, Brancasi B, D'Ursi R, Prudenzano A, et al. Clinical pharmacodynamics of acetyl-l-carnitine in patients with Parkinson's disease. Int J Clin Pharmacol Res. 1990;10(1–2):139–43.PubMed
82.
Puig T, Relat J, Marrero PF, Haro D, Brunet J, Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res. 2008;28(6A):3671–6.PubMed
83.
Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes CS, Illera JC. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17β-estradiol) in canine mammary tumours. J Steroid Biochem Mol Biol. 2008;110:76–82.PubMed
84.
Radhakrishnan Y, Busby Jr WH, Shen X, Maile LA, Clemmons DR. Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J Biol Chem. 2010;285(21):15682–95.PubMedCentralPubMed
85.
Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009;61(14):1332–42.PubMed
86.
Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther. 2008;7(9):2977–87.PubMed
87.
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115(4):450–8.PubMed
88.
Sener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N, et al. l-carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006;22(1):47–60.PubMed
89.
Sharma S, Neetu S, Wiseman DA, Carter L, Kumar S, Hou Y, et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;294:L46–56.PubMedCentralPubMed
90.
Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. l-carnitine and cancer cachexia: clinical and experimental aspects. J Cachexia Sarcopenia Muscle. 2011;2(1):37–44.PubMedCentralPubMed
91.
Singh B, Bhat NK, Bhat HK. Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness. PLoS One. 2011;6(9):e25125–36.PubMedCentralPubMed
92.
Spichiger E, Müller-Fröhlich C, Denhaerynck K, Stoll H, Hantikainen V, Dodd M. Prevalence of symptoms, with a focus on fatigue, and changes of symptoms over three months in outpatients receiving cancer chemotherapy. Swiss Med Wkly. 2011;141:w13303–13.PubMed
93.
Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol. 2005;6(8):581–8.PubMed
94.
Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, et al. Effects of toremifene and tamoxifen on lipid profiles in postmenopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol. 2010;40(7):627–33.PubMed
95.
Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012;106:6–13.PubMedCentralPubMed
96.
Tunstall RJ, McAinch AJ, Hargreaves M, van Loon LJ, Cameron-Smith D. Reduced plasma free fatty acid availability during exercise: effect on gene expression. Eur J Appl Physiol. 2007;99(5):485–93.PubMed
97.
98.
Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004;66(2):276–82.PubMed
99.
Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann NY Acad Sci. 2006;1083:329–44.PubMed
100.
Wenzel U, Nickel A, Daniel H. Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr. 2005;135(6):1510–4.PubMed
101.
Westlund KN, Lu Y, Werrbach-Perez K, Hulsebosch CE, Morgan B, Pizzo DP, et al. Effects of nerve growth factor and acetyl-l-carnitine arginyl amide on the human neuronal line HCN-1A. Int J Dev Neurosci. 1992;10(5):361–73.PubMed
102.
Winter S, Jue K, Prochazka J, Francis P, Hamilton W, Linn L, et al. The role of l-carnitine in pediatric cardiomyopathy. J Child Neurol. 1995;10(2):S45–51.PubMed
103.
Xu S, Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Transport of l-carnitine in human corneal and conjunctival epithelial cells. Mol Vis. 2010;16:1823–31.PubMedCentralPubMed
104.
Yamada S, Matsuda R, Nishimura F, Nakagawa I, Motoyama Y, Park YS, et al. Carnitine-induced senescence in glioblastoma cells. Exp Ther Med. 2012;4(1):21–5.PubMedCentralPubMed
105.
Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SGD, Sachdanandam P. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem. 2007;40:623–8.PubMed
106.
Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6(1):e16470–3.PubMedCentralPubMed
Metadata
Title
A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer
Authors
Nahla E. El-Ashmawy
Rania M. Khalil
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1477-5

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

Research Article

Haplotype-based case–control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population

Research Article

Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population

Research Article

Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer

Research Article

Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility

Research Article

Genome-wide pathway analysis in neuroblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits